Shilpa Medicare shares rise 5% after unit partners with Orion to supply nivolumab biosimilar in Europe
AI Market Summary
Shilpa Medicare\'s subsidiary signed a codevelopment and exclusive supply deal with Orion for an IV nivolumab biosimilar in Europe, with Shilpa manufacturing and Orion handling registration and commercialization. The news drove a sharp single-day equity move, but terms were not disclosed. Macro and cross-asset implications appear limited, with the impact largely confined to the company and European biosimilar competitive dynamics.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.52%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Shilpa Medicare subsidiary Shilpa Biologicals has partnered with Finland’s Orion to co-develop and exclusively supply an intravenous nivolumab biosimilar for the European market. Shilpa will manufacture the drug at its facility in Dharwad, Karnataka, while Orion will handle registration, marketing and distribution across Europe. The drug recorded about $4.1 billion in sales in Europe in 2025, based on IQVIA/IMS data cited by the company. Shilpa Medicare shares rose more than 5% after the announcement; financial terms were not disclosed, though the deal includes milestone payments and long-term supply revenue.
